Impairment tests for goodwill were performed as at 31 December 2018 for all the CGUs, to which goodwill was allocated. As a result of the tests, no need has been found to recognize impairment losses.
The goodwill impairment test involves a comparison of carrying amounts (including the allocated goodwill) and recoverable amounts of the CGUs to which goodwill has been allocated. An impairment loss for a CGU should be recognized in the profit and loss account if CGU’s recoverable amount is less than its carrying amount.
Cash-generating units (CGUs)
Goodwill is allocated to the individual companies (constituting CGUs for the purposes of the impairment test) and is monitored at this level. During the final purchase price allocation, the goodwill arising from the acquisition of Link4 was fully allocated to the mass insurance segment in non-life insurance, which – due to the scale of integration of Link4’s business with PZU under the ‘two brands’ strategy that assumed synergies resulting from the management of the mass client portfolio and sale of additional insurance products – is the smallest CGU to which goodwill can be allocated. Goodwill on the acquisition of PIM was fully allocated to Pekao, since that was the lowest level at which goodwill is monitored at the Group level.
Carrying amount
For the purposes of the test, the net carrying amount of the mass insurance segment was determined on the basis of allocation of the PZU Group’s net assets. The assets were allocated in the proportion corresponding to the ratio of the hypothetical solvency capital requirement, which may be allocated to the mass insurance segment, to the total solvency capital requirement. The Euler method was used to allocate the solvency capital requirement. This method allocates to a segment the risk measures, which are based on Solvency II regulations and take into account diversification effects.
The carrying amount of the remaining entities includes CGU’s net assets and goodwill. For the entities, in which non-controlling interests exist, the carrying amount for the purposes of the test is increased by the portion of goodwill allocated to non- controlling interests (it is not presented in the consolidated statement of financial position).
Recoverable amount
As at the balance sheet date, recoverable amount was based on value in use. As at 31 December 2017, recoverable amount was based on value in use, except for Alior Bank and Pekao, for which recoverable amount was calculated based on fair value less cost to sell. The fair value was calculated based on the stock price of Alior Bank and Pekao as quoted on the WSE on the balance sheet date plus control premium of, respectively, 10% and 5%. The costs of disposal were considered to be insignificant.
The recoverable amount of individual CGUs was determined based on value in use of the entities, using the discounted cash flow method based on the most current financial projections, for a period not exceeding 5 years, which are presented in the table below. The discount rates used for testing of the insurance companies were set at the cost of equity level. In the case of medical companies, the weighted average cost of capital (WACC) was used. The cost of equity was set in accordance with the CAPM model. Also, size premiums were applied in justified cases. Risk-free rates were determined based on the average yield of 10- year government bonds offered by the country where the CGU is domiciled and the betas were based on measures of similar listed entities. Market premiums were 5.5% (5.5% in 2017). For regulated entities (banks and insurance companies, financial institutions), the projected cash flows incorporate the requirement to maintain an adequate level of own funds (economic capital). Cash flows of the mass insurance segment were calculated based on the amount of hypothetical dividends that the segment could have paid if it had operated as a separate insurance company. The amount of dividends depends on the projected technical results of that segment, net of income tax and levy on financial institutions and capital surpluses allocated to that segment as at the balance sheet date and in subsequent periods. The growth ratios after the projection period were determined while taking into account the long term growth prospects for the market on which the entity conducts its business. In the case of insurance companies operating in the Baltic states, an adjustment was made for the expected increase in the insurance penetration rate (insurance premiums expressed as % of GDP) at 0.2-0.3 pp. In all the other cases, growth rates do not exceed the long-term GDP growth forecasts of the country in nominal terms.
Cash generating unit | 31 December 2018 | 31 December 2017 | ||||
Discount rate | Growth rate after the projection period | Timeframe of financial projections | Discount rate | Growth rate after the projection period | Timeframe of financial projections | |
Pekao | 9.4% | 3.5% | 2 years | n/a | n/a | n/a |
Alior Bank | 9.4% | 3.5% | 2 years | n/a | n/a | n/a |
Lietuvos Draudimas AB | 6.0% | 3.7% | 4 years | 5.4% | 3.7% | 5 years |
Mass insurance segment | 8.3% | 2.5% | 2 years | 8.2% | 2.5% | 3 years |
AAS Balta | 6.5% | 3.8% | 4 years | 6.2% | 3.8% | 5 years |
Medical companies | 6.7-7.6% | 2.0-3.0% | 2-5 years | 7.1% | 2.0-3.0% | 3-5 years |
Sensitivity analysis
The table on the next page presents the surplus of recoverable amounts over carrying amounts and the maximum discount rates and minimum marginal growth rates after the projection period, at which the carrying amounts and recoverable amounts of the individual CGUs. The surplus amount was stated as PZU’s share.
Cash generating unit | 31 December 2018 | 31 December 2017 | ||||
Surplus (in PLN m) | Marginal value of the discount rate | Marginal value of the growth rate after the projection period | Surplus (in PLN m) | Marginal value of the discount rate | Marginal value of the growth rate after the projection period | |
Pekao | 1,502 | 10.9% | 1.5% | n/a | n/a | n/a |
Alior Bank | 1,615 | 12.3% | (0.1%) | n/a | n/a | n/a |
Lietuvos Draudimas AB | 660 1) | 7.2% | 0.1% | 1,283 | 7.3% | 0.9% |
AAS Balta | 585 | 12.0% | (3.3%) | 439 | 11.2% | (3.2%) |
Mass insurance segment | 8,004 | 36.2% | n/a 2) | 8,204 | 37.5% | n/a 2) |
Medical companies | 102 | 8.1-32.9% | (6.3%)-3,0% | 75 | 7.6-17.4% | (24.2%)-2,5% |
1) Reduction of the surplus resulted mainly from an increase in the discount rate.
2) The amount of discounted cash flows in the projection period is higher than the carrying amount attributed to the mass insurance segment and therefore no marginal growth rate was presented after the projection period.